- FDA approves Plan B One-Step OTC switch
- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- FDA approves liquid form of enalapril to treat BP in children, adults
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
PRINCETON, N.J. — The Food and Drug Administration has approved a psychiatric drug for treating bipolar disorder when used in combination with one of two other drugs.
The FDA approved Abilify (aripiprazole), made by Bristol-Myers Squibb and Otsuka Pharmaceutical, as an adjunct to lithium or valproate for maintenance treatment of bipolar I disorder.
The FDA approved Abilify as an adjunct to lithium or valproate for acute treatment of manic or mixed episodes associated with bipolar I disorder in May 2008. The drug also is approved as a stand-alone treatment for the disorder.